Skip to main content
Astellas Pharma Inc. logo

Astellas Pharma Inc. — Investor Relations & Filings

Ticker · 4503 ISIN · JP3942400007 LEI · 529900IB708DY2HBBB35 T Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2024-02-06 Interim / Quarterly Rep…
Country JP Japan
Listing T 4503

About Astellas Pharma Inc.

https://www.astellas.com/en

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. The company's core activities encompass the research, development, manufacture, and commercialization of novel pharmaceutical products. Astellas focuses on pioneering transformative therapies in disease areas with high unmet medical needs, including oncology, ophthalmology, urology, immunology, and women's health. Through its patient-centric approach and robust research and development programs, the company aims to deliver innovative healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
四半期報告書－第19期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis (MDA), and business performance data for the third quarter of the 19th fiscal period (October 1, 2023, to December 31, 2023). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. 9M 2024
2024-02-06 Japanese
確認書
Audit Report / Information Classification · 98% confidence The document is extremely short (605 characters) and appears to be a confirmation statement ('確認書') regarding the appropriateness of the contents of a '有価証券報告書' (Securities Report/Annual Report) correction filing. It explicitly states that the company's President and CFO have confirmed the contents of the 18th period's Securities Report correction filing are appropriate based on financial instruments laws. This structure—a short confirmation document referencing a primary filing (the corrected Annual Report)—strongly suggests this is an accompanying document or a specific regulatory confirmation rather than the full Annual Report (10-K) itself. Since it is a formal confirmation related to a statutory filing, and it is not a standard earnings release (ER) or interim report (IR), it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, specific regulatory confirmation document, or potentially an Audit Report (AR) if the confirmation relates directly to the audit opinion, but RNS is safer for non-standard confirmations. FY 2023
2024-01-16 Japanese
訂正有価証券報告書－第18期(2022/04/01－2023/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains comprehensive financial data, business information, and is filed under the Financial Instruments and Exchange Act. The header explicitly identifies it as an annual securities report for the fiscal year ending March 31, 2023. FY 2022
2024-01-16 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO of Astellas Pharma Inc. regarding the accuracy of the quarterly report. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like a quarterly report), should be classified as Regulatory Filings (RNS) rather than the report itself. Q2 19
2023-11-07 Japanese
四半期報告書－第19期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Astellas Pharma Inc. with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis of financial conditions, and operating results for the second quarter of the 19th fiscal period (July 1, 2023, to September 30, 2023). It is a comprehensive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2024
2023-11-07 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It serves as a formal certification by the CEO regarding the accuracy of the quarterly report (19th term, Q1). Since this is a regulatory filing required by law to accompany financial reports but is not the financial report itself, and does not fit into specific categories like 'Annual Report' or 'Earnings Release', it falls under the general regulatory filing category.
2023-08-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.